Care Costs Lower for Practices With More High-Needs Patients

This article originally appeared here.
Share this content:
Care Costs Lower for Practices With More High-Needs Patients
Care Costs Lower for Practices With More High-Needs Patients

THURSDAY, March 16, 2017 (HealthDay News) -- Lower spending and utilization are seen for practices with a higher proportion of high-needs patients, according to a study published in the March issue of Health Affairs.

Dori A. Cross, from the University of Michigan in Ann Arbor, and colleagues examined two scale-related characteristics that could predict how well physician practices delivered care to a high-needs population: the proportion of high-needs patients in the practice and practice size. Data from four years on commercially insured, high-needs patients in Michigan primary care practices were assessed.

The researchers found that, compared with practices with smaller proportions of high-needs patients, those with a higher proportion of high-needs patients (>10 percent of the practice's panel) had lower spending and utilization. Small practices with one or two physicians had lower overall spending than large practices, but not less utilization. Performance on a composite measure of process quality was slightly worse for practices with a substantial proportion of high-need patients and for small practices, compared with their associated reference group.

"Practices that treat a high proportion of high-needs patients might have structural advantages or have developed specialized approaches to serve this population," the authors write. "If so, this raises questions about how best to make use of this knowledge to foster high-value care for high-needs patients."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths